Accueil/Actions/AIM

AIM

USD

AIM ImmunoTech Inc. Common Stock

$1.600-0.400 (-20.000%)

Prix en Temps Réel

Healthcare

Biotechnologie

États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché

Fondamentaux de l'Entreprise

Statistiques de Trading

Métriques de Marché

Ouverture

$2.000

Haut

$2.020

Bas

$1.570

Volume

0.10M

Fondamentaux de l'Entreprise

Capitalisation Boursière

4.4M

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

0.10M

Bourse

ASE

Devise

USD

Intervalle sur 52 Semaines

Bas $1.57Actuel $1.600Haut $36

Actualités Connexes

4 nov. 2025 · 14:05

GlobeNewswire

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

3 nov. 2025 · 13:55

GlobeNewswire

AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue

OCALA, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the European Patent Office has officially granted AIM's European Patent No. 4,096,675, titled